Cassava Sciences, Inc. SAVA shares are trading lower Wednesday. The company announced the top-line clinical results from its Cognition Maintenance Study where oral simufilam in patients with mild-to-moderate Alzheimer's slowed cognitive decline.
What To Know: The drug slowed cognitive decline by 38%, versus the placebo over 6 months in patients with mild-to-moderate Alzheimer's, with effects favoring a mild form of the disease.
"Monoclonal antibody drugs have slowed cognitive decline by 35% or less in early Alzheimer's patients in large Phase 3 trials over 18 months," said James Kupiec, Chief Medical Officer. "In this context, we believe results of our 6-month study are encouraging, despite vast differences in patient selection and the design and results of our randomized withdrawal study compared to large Phase 3 trials."
Related Link: Moderna Strikes mRNA Drug Pact With Chinese Authorities: Report
SAVA Price Action: Shares of SAVA were down 14.4% at $21.67 at the time of publication, according to Benzinga Pro.
Image by Michal Jarmoluk from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
